Reports

Ideas That Generate Results

Booming US Generic Drug Market

Booming US Generic Drug Market

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2011| No. of Pages : 60

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1000.00  800.00
CD-ROM Mail Delivery
US$ 1200.00  850.00
Hard Copy Mail Delivery
US$ 1200.00  900.00
Electronic Access - Multi-User License
US$ 1600.00  950.00

1. Analyst View

2. Research Methodology

3. Market Overview

4. Industry Performance and Forecast to 2013
     4.1 Branded vs Generics
     4.2 Generics Drugs Market
            4.2.1 By Value
            4.2.2 By Volume

5. Market Potential of Generics Drugs in Key Therapies Segments
     5.1 Lipid Regulators
     5.2 Antipsychotics
     5.3 Angiotensin II Receptor
     5.4 Anti Depressants
     5.5 Human Insulin
     5.6 Proton Pump Inhibitors
     5.7 Erythropoietin

6. Regulatory Environment
     6.1 Drug Efficacy Study Implementation (DESI) Program
     6.2 Hatch-Waxman Act
     6.3 Patent Infringement Litigations
     6.4 Para IV & the 180-day Marketing Exclusivity
     6.5 FDA Requirements
     6.6 Generic Initiative for Value & Efficiency (GIVE)
     6.7 Healthcare Bill 2010
     6.8 Ban on “Pay for delay” Settlements
     6.9 Patient Protection and Affordable Care Act

7. Emerging Market Trends
     7.1 Biogenerics/Biosimilar
     7.2 Anti-counterfeit Coalition
     7.3 Injectable Generics
     7.4 Patent Expiration
     7.5 Asthma & COPD Drugs

8. Key Players
     8.1 Teva Pharmaceuticals USA
     8.2 Watson Pharmaceuticals, Inc.
     8.3 Mylan Laboratories Inc.
     8.4 Pfizer Inc.
     8.5 Sandoz Inc. (Novartis)

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.